Zhang Nan, Bai Yin, Zhao Jingzhuang, Ye Xianlong, Wang Wenfei, Ren Guiping, Li Deshan, Jing Yan
Sheng Wu Gong Cheng Xue Bao. 2013 Nov;29(11):1644-53.
The aim of the study is to establish a platform to deliver therapeutic proteins into target cells through a polyarginine-based cell penetrating peptide. To facilitate the expression of therapeutic proteins, a pSUMO (Small Ubiquitin-like Modifier)-R9-EGFP (enhanced green fluorescence protein) prokaryotic expression vector was constructed. After induction, the fusion protein SUMO-R9-EGFP was efficiently expressed. To validate the cell penetrating ability of the fusion protein, HepG2 cells were incubated with the purified R9-EGFP or EGFP protein as control, internalization of the fluorescent proteins was examined by either flow cytometry or confocal microscopy. The result obtained by flow cytometry showed that the R9-EGFP fusion protein could efficiently penetrate into the HepG2 cells in a dose and time-dependent manner. In contrast, the fluorescence was barely detected in the HepG2 cells incubated with EGFP control. The fluorescence intensity of the R9-EGFP treated cells reached plateau phase after 1.5 h. The result obtained by confocal microscopy shows that R9-EGFP efficiently entered into the HepG2 cells and was exclusively located in the cytoplasm, whereas, no fluorescence was detected in the cells incubated with the EGFP control. The heparin inhibition experiment showed that heparin could inhibit penetrating effect of the R9-EGFP protein by about 50%, suggesting that the penetrating ability of the fusion protein is heparin-dependent. In summary, the study has established a platform to deliver therapeutic proteins into target cells through a polyarginine-based penetrating peptide.
本研究的目的是建立一个平台,通过基于聚精氨酸的细胞穿透肽将治疗性蛋白质递送至靶细胞。为促进治疗性蛋白质的表达,构建了一个pSUMO(小泛素样修饰物)-R9-EGFP(增强型绿色荧光蛋白)原核表达载体。诱导后,融合蛋白SUMO-R9-EGFP高效表达。为验证融合蛋白的细胞穿透能力,将纯化的R9-EGFP或作为对照的EGFP蛋白与HepG2细胞一起孵育,通过流式细胞术或共聚焦显微镜检查荧光蛋白的内化情况。流式细胞术获得的结果表明,R9-EGFP融合蛋白能够以剂量和时间依赖性方式有效穿透HepG2细胞。相比之下,在与EGFP对照孵育的HepG2细胞中几乎检测不到荧光。R9-EGFP处理的细胞的荧光强度在1.5小时后达到平台期。共聚焦显微镜获得的结果表明,R9-EGFP有效进入HepG2细胞并仅位于细胞质中,而在与EGFP对照孵育的细胞中未检测到荧光。肝素抑制实验表明,肝素可将R9-EGFP蛋白的穿透作用抑制约50%,表明融合蛋白的穿透能力依赖于肝素。总之,本研究建立了一个通过基于聚精氨酸的穿透肽将治疗性蛋白质递送至靶细胞的平台。